DVAX - Dynavax Technologies Corporation
About Dynavax Technologies Corporation (https://www.dynavax.com)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Ryan Spencer | Chief Executive Officer & Director | 1979 | $1,484,326 USD |
| David F. Novack | Senior VP & COO | 1962 | $965,313 USD |
| Robert Janssen | Chief Medical Officer and Senior Vice President of Clinical Development, Medical & Regulatory Affairs | 1954 | $827,719 USD |
| John Slebir | Senior Vice President & General Counsel | 1965 | $809,129 USD |
| Kelly MacDonald | Senior Vice President & Chief Financial Officer | 1984 | $733,501 USD |
| Dong Yu | Senior Vice President of Research | – | – |
| Donn Casale | Senior Vice President & Chief Commercial Officer | – | – |
| Eric Frings | Vice President, Site Head & MD for Dynavax GmbH | – | – |
| Jeff Coon | Senior Vice President & Chief Human Resources Officer | 1963 | – |
| Joseph Metzinger | Vice President & Chief Accounting Officer | 1984 | – |
| Meg Smith | Senior Vice President of Commercial | – | – |
| Paul Cox | Vice President of Investor Relations & Corporate Communications | – | – |